New drug combo shows promise against rare bone marrow cancer

NCT ID NCT03069326

First seen Mar 12, 2026 · Last updated Apr 25, 2026 · Updated 5 times

Summary

This study tests whether combining two drugs, ruxolitinib and thalidomide, can shrink the cancer and improve symptoms in people with myelofibrosis, a rare bone marrow disorder. About 30 adults with the disease, including those who have tried other treatments, will receive the combination. The goal is to see if the drugs work better together than alone, while monitoring for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.